医学
内科学
淋巴瘤
化疗
移植
造血干细胞移植
外周T细胞淋巴瘤
肿瘤科
外科
胃肠病学
癌症
存活率
T细胞淋巴瘤
免疫学
T细胞
免疫系统
作者
José A. Rodríguez,Mark F. Munsell,S. Yazji,Fredrick B. Hagemeister,Anas Younes,Börje S. Andersson,Sergío Giralt,J. Gajewski,Marcos de Lima,Daniel R. Couriel,Jorge Romaguera,Fernando Cabanillas,Richard E. Champlin,Issa F. Khouri
标识
DOI:10.1200/jco.2001.19.17.3766
摘要
PURPOSE: To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma (PTCL) who experienced disease recurrence after prior conventional chemotherapy. PATIENTS AND METHODS: We performed a retrospective analysis of 36 PTCL patients from the University of Texas M.D. Anderson Cancer Center treated between 1989 and 1998 with HDCT and autologous or allogeneic hematopoietic transplantation. RESULTS: A total of 36 patients were studied (29 received autologous transplantation, and seven received allogeneic transplantation). The overall survival rate at 3 years was 36% (95% confidence interval [CI], 23% to 59%), and the progression-free survival (PFS) rate was 28% (95% CI, 16% to 49%). The pretransplant serum lactate dehydrogenase level was the most important prognostic factor for both survival and PFS rates (P < .001). A Pretransplant International Prognostic Index score of ≤ 1 indicated a superior survival rate (P = .036) but not an improved PFS rate. A median follow-up of 43 months (range, 13 to 126 months) showed 13 patients (36%) were still alive with no evidence of disease. CONCLUSION: Our results are comparable to the published data on HDCT in B-cell non-Hodgkin’s lymphoma (NHL) patients despite the fact that patients with PTCL are known to have a worse outcome compared with B-cell NHL patients. Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation.
科研通智能强力驱动
Strongly Powered by AbleSci AI